The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor / 임상당뇨병
Journal of Korean Diabetes
;
: 158-162, 2014.
Artículo
en Coreano
| WPRIM
| ID: wpr-726968
ABSTRACT
Anti-diabetic drugs for effectively lowering glucose with limited side effects are necessary in providing patient-centered diabetic management. Sodium glucose cotransporter 2 (SGLT 2) inhibitors provide a novel therapeutic approach for managing type 2 diabetic patients by lowering glucose levels by increasing urinary excretion of glucose independently of insulin secretion or action. Several SGLT 2 inhibitors were recently approved and available in the US, European and Korean markets. SGLT 2 improved glycemic control with low propensity of hypoglycemia. Through the clinical trials, most SLGT2 inhibitors were generally well tolerated. Genital tract infections were more frequent in most clinical studies of SGLT2 inhibitors and urinary tract infections were slightly increased in some studies. This review will describe the main safety issues that have been uncovered in clinical trials of SGLT 2 inhibitors.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Sodio
/
Infecciones Urinarias
/
Diabetes Mellitus Tipo 2
/
Infecciones del Sistema Genital
/
Glucosa
/
Hipoglucemia
/
Insulina
Límite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Diabetes
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS